Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 3, 2010, Pages 315-322

  Ashikaga, Eijin ^a   Honda, Hirokazu ^a   Suzuki, Hiroki ^a   Hosaka, Nozomu ^a   Hirai, Yuki ^a   Sanada, Daisuke ^a   Nakamura, Mari ^a   Nagai, Hisako ^a   Matsumoto, Kei ^a   Kato, Noriyuki ^a   Mukai, Masanori ^a   Watanabe, Makoto ^a   Takahashi, Keiko ^b   Shishido, Kanji ^b   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kawasaki Clinic   (Japan)

Author keywords

Atherosclerosis; Fibroblast growth factor 23; Hemodialysis; Lipid abnormality

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CELLULOSE ACETATE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; POLYSULFONE; VITAMIN D; FIBROBLAST GROWTH FACTOR;

AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; B SCAN; BLOOD SAMPLING; CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GERIATRIC NUTRITION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS BLOOD; BLOOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77952926817     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00796.x     Document Type: Article

References (28)

1. Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients - clinical implications and therapeutic guidelines. Ther Apher Dial 2006 10 : 305 315.
2. Ogata H, Koiwa F, Kinugasa E, Akizawa T. Ckd-mbd: impact on management of kidney disease. Clin Exp Nephrol 2007 11 : 261 268.
3. Fukumoto S. Physiological regulation and disorders of phosphate metabolism - pivotal role of fibroblast growth factor 23. Intern Med 2008 47 : 337 343.
4. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: Regulation by phosphate? Bone 2004 35 : 1192 1199.
5. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001 98 : 6500 6505.
6. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001 86 : 497 500.
7. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001 60 : 2079 2086.
8. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004 65 : 1943 1946.
9. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin d metabolism. J Clin Invest 2004 113 : 561 568.
10. Lanske B, Razzaque MS. Premature aging in klotho mutant mice: Cause or consequence? Ageing Res Rev 2007 6 : 73 9.
11. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003 41 : I IV, S1-91.
12. Kazama JJ. Japanese society of dialysis therapy treatment guidelines for secondary hyperparathyroidism. Ther Apher Dial 2007 11 (Suppl 1 S44 47.
13. Yamada K, Furuya R, Takita T et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 2008 87 : 106 113.
14. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993 4 : 1205 1213.
15. Shinzato T, Nakai S, Fujita Y et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994 67 : 280 290.
16. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000 277 : 494 498.
17. Tomlinson E, Fu L, John L et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002 143 : 1741 1747.
18. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005 115 : 1627 1635.
19. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFr4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007 56 : 2501 2510.
20. Yu X, White KE. Fibroblast growth factor 23 and its receptors. Ther Apher Dial 2005 9 : 308 312.
21. Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005 146 : 4647 4656.
22. Imel EA, Peacock M, Pitukcheewanont P et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006 91 : 2055 2061.
23. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006 17 : 1506 1513.
24. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008 359 : 584 592.
25. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 2005 45 : 1067 1072.
26. Bernini G, Galetta F, Franzoni F et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008 26 : 2399 2405.
27. Nagano K, Yamagami H, Tsukamoto Y et al. Quantitative evaluation of carotid plaque echogenicity by integrated backscatter analysis. Correlation with symptomatic history and histologic findings. Cerebrovasc Dis 2008 26 : 578 583.
28. Rossi M, Cupisti A, Santoro G, Morelli E, Meola M, Barsotti G. Ultrasonic tissue characterization of the carotid artery in chronic renal failure patients. Nephron 2002 91 : 270 275.